Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d three years and older are planned to enroll in the trial, which is targeted to be conducted in 10 to 15 sites across the US, Europe and Canada. The study will comprise ABH001 applications sufficient to cover the surface area of the wound, applied topically every 4 weeks with protocol-specified dressings until healed or for up to 24 weeks.

"We are excited that Shire Regenerative Medicine has launched this trial," said Brett Kopelan , Executive Director of the Dystrophic EB Research Association of America (DebRA ) and father to a 5-year-old girl with recessive dystrophic EB.  "While there is currently no cure for EB, I am encouraged that ABH001 is…targeting the chronic wounds that are the hallmark of this disease. I applaud Shire for pushing this forward and look forward to working closely with them as the trial progresses."  

"We are very eager to begin evaluating ABH001 as a potential wound treatment option for people with EB. We believe it has the potential to initiate and continue wound healing in this patient population," said Jeff Jonas , MD, President of Shire Regenerative Medicine. "We are committed to developing regenerative medicine solutions that enable people with life-altering conditions to lead better lives, and are encouraged by the fast track and orphan drug designations we have received to further develop this potential therapy for people, most often young children, suffering from this devastating condition."

Shire is also developing an intravenous protein replacement therapy for the treatment of dystrophic EB, which the company's Human Genetic Therapies business recently acquired from Lotus Tissue Repair, Inc. Initiation of this pivotal trial of ABH001 for patients with EB further demonstrates Shire's commitment to developing a portfolio of products targeted toward patients who suffer from this di
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... Aurigene and its partner ... presenting data at the poster sessions from two ... Annual Meeting (April 18-22 in Philadelphia, ... http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene will present ... molecule inhibitors program, which is currently in preclinical ...
(Date:4/17/2015)... 2015 Reed Technology and Information ... data management, preparation, and submission to the U.S. Food ... a new Lot Distribution Report (LDR) service for manufacturers ... compliant with the FDA’s new rule on electronic submission ... monitor the volume and timing of particular biologics introduced ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
Breaking Biology Technology:Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... Been Filed With the FDA for the Fourth Genmab ... Under the Company,s Collaboration with Roche., COPENHAGEN, December ... Investigational New Drug application (IND) for a,Genmab antibody developed ... the FDA by Roche. Genentech and Roche are collaborating ...
... Dec. 11 The Tauri Group LLC is ... provide Systems Engineering and,Technical Assistance (SETA) support for ... Health Affairs Early Detection Division Chemical,and Biological Early ... $38 million and the period of performance is ...
... 11 PPD, Inc. (Nasdaq:,PPDI) will release its fiscal ... the market closes. The release will be available on,the ... PR Newswire., On Wednesday, January 9, 2008, at ... and audio webcast to discuss its financial guidance for,fiscal ...
Cached Biology Technology:Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract 2PPD Announces 2008 Financial Guidance Webcast and Conference Call 2
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... unique aroma signature of the durian revered as the ... the world,s foulest smelling food has uncovered several new ... ACS, Journal of Agricultural and Food Chemistry . ... food shops in the United States and elsewhere, has a ...
... in a Duke University-led study contained potentially toxic or untested chemical ... Among the chemicals detected was "Tris," a chlorinated flame ... studies. "Tris was phased out from use in ... it still showed up in 41 percent of the couch foam ...
... Toronto, ON (27 November, 2012) -- A new method of ... The discovery, which transforms aged stem cells into cells that ... to grow cardiac patches for damaged or diseased hearts from ... avoiding the threat of rejection. Stem cell therapies ...
Cached Biology News:Potentially toxic flame retardants found in many US couches 2'Fountain of youth' technique rejuvenates aging stem cells 2
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... high-performance triple quadrupole 1200L sets the ... cost-conscious environment - incorporating the latest ... all liquid chromatography analytical needs. ... and the Transmission Quadrupole Analyzer provide ...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: